menu
    • menu
    [{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Yale University | National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BMS-984923","moa":"Metabotropic glutamate receptor 5 (mGluR5)","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allyx Therapeutics \/ Yale University | National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Yale University | National Institute on Aging"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BMS-984923","moa":"Metabotropic glutamate receptor 5 (mGluR5)","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allyx Therapeutics \/ Michael J. Fox Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Michael J. Fox Foundation"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BMS-984923","moa":"Metabotropic glutamate receptor 5 (mGluR5)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allyx Therapeutics \/ National Institute on Aging","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ National Institute on Aging"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BMS-984923","moa":"Metabotropic glutamate receptor 5 (mGluR5)","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allyx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Yale University","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BMS-984923","moa":"Metabotropic glutamate receptor 5 (mGluR5)","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allyx Therapeutics \/ Yale University","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Yale University"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BMS-984923","moa":"Metabotropic glutamate receptor 5 (mGluR5)","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allyx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BMS-984923","moa":"Metabotropic glutamate receptor 5 (mGluR5)","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allyx Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BMS-984923","moa":"Metabotropic glutamate receptor 5 (mGluR5)","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allyx Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"BMS-984923","moa":"Metabotropic glutamate receptor 5 (mGluR5)","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allyx Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Allyx Therapeutics","sponsor":"Michael J. Fox Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BMS-9894923","moa":"mGluR5","graph1":"Neurology","graph2":"Phase I","graph3":"Allyx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allyx Therapeutics \/ Michael J. Fox Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Allyx Therapeutics \/ Michael J. Fox Foundation"}]

    Find Clinical Drug Pipeline Developments & Deals by Allyx Therapeutics

    Menu

    Allyx Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMS-984923

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : National Institutes of Health

                            Deal Size : $3.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Allyx Therapeutics Receives $3.3M NIH Grant for ALX-001 Clinical Studies

                            Details : The funding will support Allyx’s ALX-001, a highly-selective, first-in-class, synapse-targeted, disease-modifying oral therapy in development for Alzheimer’s disease and Parkinson’s disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 15, 2024

                            Lead Product(s) : BMS-984923

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : National Institutes of Health

                            Deal Size : $3.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMS-984923

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : National Institute on Aging

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Pro...

                            Details : BMS-984923 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 09, 2024

                            Lead Product(s) : BMS-984923

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : National Institute on Aging

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMS-984923

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allyx Therapeutics Announces First Parkinson’s Disease Patient Treated with ALX-001

                            Details : ALX-001 (previously BMS-984923) is a oral silent allosteric modulator of mGluR5, which is being evaluated for the treatment of patients with parkinson’s disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 04, 2024

                            Lead Product(s) : BMS-984923

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMS-984923

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Yale University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allyx Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001

                            Details : ALX-001 (previously BMS-984923) is a oral silent allosteric modulator of mGluR5, which is being evaluated for the treatment of patients with alzheimer’s disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 11, 2024

                            Lead Product(s) : BMS-984923

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Yale University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMS-9894923

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Michael J. Fox Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's

                            Details : BMS-9894923 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 13, 2024

                            Lead Product(s) : BMS-9894923

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Michael J. Fox Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMS-984923

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allyx Therapeutics Announces Positive Phase 1b Data and Advances ALX-001 to Patients

                            Details : BMS-984923 (ALX-001) is a highly selective, first-in-class, synapse-targeted, disease-modifying oral therapy, which is being evaluated for the treatment of Alzheimer’s and Parkinson’s disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 11, 2024

                            Lead Product(s) : BMS-984923

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMS-984923

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allyx Expands into Parkinson's Disease Research with ALX-001 Following IND Acceptance

                            Details : ALX-001 is a highly selective, first-in-class, synapse-targeted, disease-modifying oral therapy for neurodegenerative diseases. It is being evaluated for the treatment of Parkinson’s Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 05, 2024

                            Lead Product(s) : BMS-984923

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMS-984923

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allyx Therapeutics Lead Compound ALX-001 is Safe and Tolerable at Doses, Achieving Full Brain Target Engagemen...

                            Details : ALX-001 (previously BMS-984923) is a oral silent allosteric modulator of mGluR5, and the first-in-class compound that selectively blocks the pathogenic activation of the receptor while preserving normal glutamate signaling, being investigated for neurode...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 30, 2023

                            Lead Product(s) : BMS-984923

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMS-984923

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Michael J. Fox Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers

                            Details : BMS-984923 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 18, 2023

                            Lead Product(s) : BMS-984923

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Michael J. Fox Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Allyx Therapeutics

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMS-984923

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Yale University | National Institute on Aging

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease

                            Details : BMS-984923 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 07, 2023

                            Lead Product(s) : BMS-984923

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Yale University | National Institute on Aging

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth